After a year of struggling to reach the finish line, Thousand Oaks-based Atara Biotherapeutics is knocking on the door again. The biotech company, which is aiming to create therapies for patients with cancer and autoimmune diseases, announced Sept. 30 that it has resubmitted the tabelecleucel Biologics License Application to the U.S. Food and Drug Administration,…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
